The 7-OH Science Fraud
Every major preclinical 7-OH study injects isolated alkaloid at doses no oral kratom user can reach. The FDA's own 2025 document admits no human clinical studies exist. This is not science. This is weaponized methodology serving pharmaceutical financial interests.
TL;DR: The Methodological Gap
- Route of administration is the central problem. Every major preclinical study on 7-OH pharmacology used subcutaneous, intravenous, or intraperitoneal injection. Kratom is consumed orally. These are not comparable delivery routes. The injection route bypasses the oral bioavailability constraints and the emetic ceiling that govern real-world kratom use.
- The FDA acknowledges the human evidence gap directly. The FDA's own 2025 CDER assessment states that "no clinical studies have been performed using isolated or purified 7-hydroxymitragynine" in humans. The human adverse event record is 13 FAERS cases, most involving polydrug use, in a user population numbering in the millions.
- The most cited study found mitragynine showed no abuse potential. Hemby et al. (2019), the primary abuse-liability study cited in regulatory proceedings, found that mitragynine, kratom's primary alkaloid comprising 60 to 70 percent of alkaloid content, did not self-administer at any dose tested in the same IV paradigm. This finding is rarely foregrounded in regulatory summaries.
- Three distinct product categories are being conflated. Natural kratom leaf, concentrated botanical extracts, and high-dose manufactured 7-OH products are being treated as one regulatory target. The FDA's own document acknowledges that concentrated 7-OH products require chemical steps beyond standard extraction. Conclusions drawn from studies on isolated synthetic compounds are being applied to natural leaf products.
- The word fraud is appropriate. Researchers who publish in pharmacology journals understand that route of administration is fundamental. Regulatory scientists who cite those studies in scheduling proceedings know that kratom is consumed orally. Presenting injection findings as evidence of oral consumer risk, in proceedings where the conclusion serves a documented financial interest, is not an oversight. It is a choice.
Route of Administration Is Not a Minor Detail
In pharmacology, the route by which a compound enters the body is one of the most fundamental variables in determining its effects. Intravenous injection and oral consumption are not interchangeable in any meaningful scientific sense.
Every person who consumes kratom does so orally, as tea, powder, capsule, or liquid extract swallowed by mouth. The compound travels through the gastrointestinal tract, is processed by first-pass hepatic metabolism, and what remains reaches systemic circulation. This process substantially reduces the fraction of the compound that reaches the bloodstream, slows the onset of any effects, and dramatically lowers the peak plasma concentration compared to direct injection.
Injection bypasses every one of these constraints. An intravenous dose delivers the compound directly into the bloodstream at 100 percent bioavailability with an immediate onset. A subcutaneous dose is absorbed more slowly than IV but still avoids gastrointestinal and first-pass processing entirely. The pharmacological context produced by injection has no real-world analog in kratom consumption.
Route of Administration in Every Major 7-OH Preclinical Study
| Study | Route Used | Route of Human Kratom Use |
|---|---|---|
| Matsumoto et al. (2004), antinociception, "more potent than morphine" | Subcutaneous (SC) injection | Oral |
| Matsumoto et al. (2008), opioid receptor characterization | Subcutaneous (SC) injection | |
| Hemby et al. (2019), abuse liability, self-administration | Intravenous (IV) catheter | |
| Obeng et al. (2021), mu-opioid pharmacology in rats | Intravenous (IV) administration | |
| Zuarth Gonzalez et al. (2026), respiratory effects in rats | Intravenous (IV) administration |
Human kratom consumption route in all documented use: oral. Number of these studies that used oral administration to model human kratom risk: zero.
The Emetic Ceiling
There is a specific, documented biological mechanism that makes the injection-to-oral translation particularly problematic for kratom. Kratom consumers are familiar with the nausea that results from consuming too much. It is an effective and well-documented dose limiter. The body's emetic response functions as a ceiling on how much kratom an oral consumer can take, and therefore on how much 7-OH can reach systemic circulation through oral consumption.
Injection eliminates this ceiling entirely. An IV dose that would produce immediate vomiting if consumed orally can be delivered in its entirety, bypassing the biological constraint that defines the upper limit of real-world kratom use. This is not a small pharmacological detail. It means the injection-dose studies are exploring a pharmacological territory that is mechanically inaccessible to any oral kratom consumer.
What the "More Potent Than Morphine" Claim Actually Means
The most widely cited finding from 7-OH preclinical research is that it is "more potent than morphine," originating in Matsumoto et al. (2004). What that study found: when injected subcutaneously into rodents, 7-OH produced analgesia at lower mg/kg doses than subcutaneously injected morphine in standard pain assays.
Potency-per-milligram-injected is not the same as risk to a human oral consumer. The finding tells you how much injected 7-OH, relative to injected morphine, is needed to produce a specific effect in a rodent pain model. It does not tell you what dose of 7-OH a kratom consumer receives orally, or how that dose compares to the study's injected doses after accounting for bioavailability differences and the emetic ceiling.
This finding is routinely cited in regulatory proceedings as if it were a statement about the risk profile of kratom products for human consumers. It is not that statement.
The Dose Question: A Clarification
Prior discussions of this topic have sometimes compared animal study doses to human exposure by simple weight multiplication, which overstates the gap. The correct method, per FDA's 2005 guidance on interspecies dose translation, uses body surface area conversion factors. A 10 mg/kg mouse dose translates to approximately 55 to 60 mg human-equivalent dose, not 680 mg. A 10 mg/kg rat dose translates to approximately 110 mg human-equivalent, not 680 mg.
These correctly converted doses are meaningfully higher than what a natural kratom leaf serving delivers, but they are in the same order of magnitude as the 5 to 50 mg oral doses reported by isolate product users. The point is not a dramatic numerical gap. The point is that the route is categorically different regardless of how the doses compare, and the emetic ceiling specifically ensures that real-world oral consumers cannot access the plasma concentrations the injection studies produce even if they tried.
What the Same Studies Found That Regulatory Summaries Don't Emphasize
The preclinical studies cited in regulatory proceedings contain findings that complicate the conclusions being drawn from them. These findings appear in the same papers. They are not prominently foregrounded in regulatory summaries.
Hemby et al. (2019): The Buried Finding
The primary study cited for 7-OH's abuse liability is Hemby et al. (2019), published in Addiction Biology. The study used an intravenous self-administration paradigm in rodents, a standard method for assessing whether a compound has reinforcing properties in an IV drug model. The study found that rodents would self-administer 7-OH at certain unit IV doses.
The same study tested mitragynine, kratom's primary alkaloid, which comprises 60 to 70 percent of the plant's alkaloid content. The study found that mitragynine did not self-administer at any dose tested in the same IV paradigm.
The substance constituting the overwhelming majority of kratom's active alkaloid profile showed no abuse potential in the same study being used to establish that kratom-derived compounds have high abuse potential. This finding appears in the study. It is not prominently featured in the regulatory summaries of it.
Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Addiction Biology. 2019;24(5):874-885.
The In Vitro Receptor Work: What It Actually Shows
Kruegel et al. (2016), published in the Journal of the American Chemical Society, characterized the receptor binding profile of kratom alkaloids. The in vitro work established that 7-OH is a partial agonist at the mu-opioid receptor with a biased signaling profile: it produces reduced beta-arrestin recruitment compared to classical full mu-opioid agonists like morphine.
Beta-arrestin-2 recruitment is associated with respiratory depression in opioid pharmacology. Whether reduced beta-arrestin recruitment in vitro directly translates to reduced respiratory depression risk in vivo is scientifically contested. The relationship is not as simple as the in vitro data might suggest, and some subsequent research has complicated the picture. This cannot be stated as a settled safety advantage; the honest framing is that the receptor profile is meaningfully different from classical opioids in a way that may have clinical relevance but has not been established in human clinical trials.
What Is and Is Not Established About 7-OH's Receptor Profile
Established (in vitro): 7-OH is a partial agonist at the mu-opioid receptor with reduced beta-arrestin-2 recruitment compared to morphine (Kruegel et al., 2016; Obeng et al., 2021). This is pharmacologically meaningful and distinguishes it from full agonists.
Not established (in vivo, human): Whether this receptor profile translates to meaningfully reduced respiratory depression risk in real-world human use has not been tested in any human clinical study. The FDA's own assessment acknowledges that no human clinical studies have been conducted on isolated or purified 7-OH.
Contested: The beta-arrestin-2 hypothesis for opioid respiratory depression has faced challenges in subsequent research. The claim that biased agonism straightforwardly produces safer opioids is an active area of scientific debate, not settled pharmacology.
The Human Evidence the FDA Acknowledges Is Not There
Schedule I placement requires a finding of high abuse potential with no currently accepted medical use. The evidentiary standard for the most restrictive classification in federal law should be high. Here is what the human evidence actually consists of.
"No clinical studies have been performed using isolated or purified 7-hydroxymitragynine."
FDA Center for Drug Evaluation and Research, Reissig et al., 2025. Available at: fda.gov/media/187899/download
This is the FDA's own document, specifically prepared to support the scheduling recommendation. Its acknowledgment that no human clinical studies exist on the compound in question is not an obscure technical footnote. It is the foundational evidentiary problem for a Schedule I action, which by definition applies a "no accepted medical use" standard that would ordinarily require actual human data to meaningfully apply.
What the human record consists of, per the same document: adverse event reports from voluntary reporting systems. FAERS, the FDA Adverse Event Reporting System, received a small number of cases specifically involving 7-OH. The document notes that interpretation of these cases is limited by ambiguity about causation, polydrug involvement, and the inherent limitations of voluntary adverse event reporting, which requires no causal determination and cannot establish that a specific compound caused a specific outcome.
The Adverse Event Record in Context
The FAERS adverse event cases cited in the regulatory assessment involve polydrug use in most documented instances. FDA's own assessment notes that "ambiguity limits interpretation" of the cases attributed to 7-OH specifically.
Kratom in various forms has millions of regular users in the United States. Survey research, including Garcia-Romeu et al. (2020) from Johns Hopkins, documented user patterns and outcomes across nearly 3,000 respondents and found that most reported using kratom for pain management and opioid transition, with the majority reporting positive outcomes.
Against a user population of this size, a small number of ambiguous, polydrug FAERS reports is not a statistical signal. It is the practical floor of what voluntary adverse event reporting generates for any substance used by millions of people. It says very little about causation and nothing about the safety profile of normal-dose oral kratom use in the absence of polydrug involvement.
What Zero Human Clinical Studies Means for the Regulatory Conclusion
The preclinical studies are being used to fill a gap that can only be honestly addressed by human clinical research that does not exist. This creates a specific epistemic problem: the gap between what the injection studies can establish and what the regulatory conclusion requires is not bridged by any data. It is bridged by an inference from IV rodent pharmacology to human oral consumer risk, a gap that the route-of-administration difference makes particularly unreliable.
That inference is not acknowledged explicitly in the regulatory assessment as an inference. It is presented as a straightforward application of existing research to a regulatory question. The existing research does not support the question it is being asked to answer.
Three Products, One Regulatory Target
The regulatory action treats natural kratom leaf, concentrated botanical extracts, and high-dose manufactured 7-OH products as a single category. The FDA's own document acknowledges they are not.
7-hydroxymitragynine occurs naturally in the kratom leaf at concentrations documented at 0.01 to 0.04 percent by dry weight, per multiple independent analyses and the FDA's own CDER assessment. A five-gram serving of natural kratom leaf powder contains, at these concentrations, approximately 0.5 to 2 milligrams of naturally occurring 7-OH, consumed orally.
Concentrated 7-OH products, specifically the gummies, shots, and high-dose tablets that have driven the regulatory concern, are a different product category. The FDA's own 2025 CDER assessment states that concentrating 7-OH to the levels found in these products requires "additional chemical synthetic steps beyond simple extraction." These are manufactured products, produced through a deliberate concentration process, delivering 15 milligrams or more of 7-OH per dose.
"The direct extraction of 7-OH from plant material would simply be unfeasible economically... [concentrated 7-OH products] require additional chemical synthetic steps beyond simple extraction."
Reissig et al., FDA CDER, 2025. fda.gov/media/187899/download
The distinction matters for the regulatory analysis because the preclinical studies were conducted on isolated, purified 7-OH, not on natural kratom leaf. Adverse event data from users of high-dose manufactured products is not cleanly distinguishable from data involving natural leaf users in FAERS or NPDS reporting. A ban on 7-OH based on concerns about concentrated manufactured products applies with equal legal force to natural kratom leaf containing the compound at trace concentrations, because both contain the scheduled substance.
The Contamination Issue the Ban Does Not Solve
A portion of the documented adverse events attributed to kratom and 7-OH products involve contamination with other substances. Tianeptine, which has severe opioid-like dependence properties, has been found in products marketed as kratom or kratom extracts. FAERS and NPDS data cannot distinguish a case where 7-OH caused an adverse event from a case where a tianeptine-contaminated product caused it.
Prohibition of 7-OH does not address contamination. It eliminates the legal, potentially testable and regulated market while the unregulated market, where contamination is undisclosed and unchecked, continues to operate. Mandatory testing and labeling requirements, as established in KCPA-framework states, directly address contamination. A scheduling action does not.
A Methodological Gap, Clearly Stated
Using injection studies to characterize oral consumer risk is not an innocent methodological mismatch. Researchers who publish in pharmacology journals know that route of administration is fundamental to any meaningful risk characterization. Regulatory scientists who cite those studies in scheduling proceedings know that kratom is consumed orally. Presenting injection findings as evidence of oral consumer risk, in proceedings where the conclusion serves a documented financial interest, is not an oversight. It is a choice. The word fraud is appropriate.
The problem is the application. Regulatory proceedings are using injection-route rodent studies as the primary evidence base for a scheduling action that affects oral consumer risk from botanical products. The route of administration used in every major study is categorically different from the route used by every kratom consumer. No human clinical studies have been conducted on isolated 7-OH, a fact the FDA's own document acknowledges. The adverse event record, consisting of a small number of ambiguous, polydrug FAERS reports, does not establish causation for any outcome.
These are not arguable interpretive points. They are documented facts about the study designs, the routes used, and the state of the human evidence. They are in the primary sources. The preclinical research cannot answer the question the regulatory action asks it to answer, because the methodology required to answer that question has not been conducted.
The appropriate response to a genuine safety concern about concentrated, manufactured 7-OH products is a regulatory framework requiring mandatory testing, labeling, and adulterant screening. That framework exists and is operating in more than 20 states under the Kratom Consumer Protection Act. It addresses the documented problems. It does not apply conclusions from IV rodent studies to millions of oral botanical product consumers who were never studied.
This is not science. This is weaponized methodology serving pharmaceutical financial interests.
A Note on Sources and Methodology
Every claim in this investigation is drawn from primary sources: the FDA CDER assessment (Reissig et al., 2025, publicly available at fda.gov/media/187899/download), Hemby et al. (2019) in Addiction Biology, Matsumoto et al. (2004) in Life Sciences, Kruegel et al. (2016) in the Journal of the American Chemical Society, Obeng et al. (2021) in the Journal of Pharmacology and Experimental Therapeutics, and Garcia-Romeu et al. (2020) in Drug and Alcohol Dependence. The dose conversion methodology referenced in Part 1 follows FDA's 2005 guidance on interspecies dose translation, which uses body surface area factors rather than simple weight multiplication. The data in the cited studies is not disputed. What is disputed is its application to a regulatory question the study designs were never suited to answer.
Continue the Investigation
How a Crisis Gets Built
No single-substance kratom deaths. A manufactured escalation. An inflated adverse-event count. The full primary-source investigation into the statistics behind the bans.
Does 7-OH Meet the Legal Standard?
The specific statutory test the DEA must clear for emergency scheduling, read against its own record. The 2018 HHS prior finding it never addresses.
The Patent Race
MSKCC and Columbia hold patents on kratom-derived compounds. Sparian Biosciences and Kures are developing the prescription replacements. The cannabis playbook, documented.
Primary Sources
Every claim in this investigation is verifiable from publicly available primary documents.
Regulatory Document
- Reissig CJ, et al. FDA Center for Drug Evaluation and Research (CDER). (2025). Assessment of 7-hydroxymitragynine. Publicly available at: fda.gov/media/187899/download. [Source for: "no clinical studies have been performed using isolated or purified 7-OH"; "additional chemical synthetic steps"; 7-OH alkaloid concentration range 0.01-0.04%]
Preclinical Studies
- Matsumoto K, Horie S, Ishikawa H, et al. Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sciences. 2004;74(17):2143-2155. [SC injection; origin of "more potent than morphine" claim]
- Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse Liability and Therapeutic Potential of the Mitragyna speciosa (Kratom) Alkaloids Mitragynine and 7-Hydroxymitragynine. Addiction Biology. 2019;24(5):874-885. [IV self-administration; mitragynine did not self-administer at any dose]
- Obeng S, Wilkerson JL, Leon F, et al. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for mu-Opioid Receptor and Opioid-Like Behavioral Effects in Rats. Journal of Pharmacology and Experimental Therapeutics. 2021;376(3):410-427. [IV administration; mu-opioid pharmacology]
- Zuarth Gonzalez JD, Ragsdale AK, Mukhopadhyay S, et al. Mitragynine and 7-hydroxymitragynine: Bidirectional effects on breathing in rats. Journal of Pharmacology and Experimental Therapeutics. 2026;393(5):104326. [IV administration; respiratory effects in rats]
- Kruegel AC, Gassaway MM, Bhatt A, et al. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. Journal of the American Chemical Society. 2016;138(21):6754-6764. [In vitro receptor binding; biased agonism; reduced beta-arrestin-2 recruitment]
Human Population Research
- Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Weiss RD. Kratom (Mitragyna speciosa): User motivations, effects and harms. Drug and Alcohol Dependence. 2020;208:107849. [Survey of approximately 2,800 kratom users; pain management and opioid transition primary use cases]
Dose Conversion Methodology
- FDA. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. FDA/CDER, 2005. [Body surface area conversion factors for interspecies dose translation: mouse-to-human factor 12.3, rat-to-human factor 6.2]
The Route Is the Argument
No kratom user injects anything. Every major 7-OH study used injection. FDA admits no human clinical studies exist. Presenting injection findings as oral consumer risk evidence, while holding patents on the synthetic replacement, is not an oversight. It is a choice.